窥知

Clinical Atlas of Interstitial Lung Disease (Springer, 2006).pdf Clinical Atlas of Interstitial Lung Disease Tatjana Peroš-Golubičić , MD, PhD, and Om P. Sharma, MD, FRCP Clinical Atlas of Interstitial Lung Disease Foreword by Talmadge E. King, Jr., MD Tatjana Peroš-Golubičić , MD, PhD University of Zagreb Medical School University Hospital for Lung Diseases “Jordanovac” Zagreb Croatia Om P. Sharma, MD, FRCP Keck School of Medicine at University of Southern California Los Angeles, California USA British Library Cataloguing in Publication Data Peroš-Golubičić , Tatjana Clinical atlas of interstitial lung disease 1. Interstitial lung diseases—Atlases I. Title II. Sharma, Om P. 616.2′4 ISBN-13: 9781846283208 ISBN-10: 1846283205 Library of Congress Control Number: 2005938495 ISBN-10: 1-84628-320-5 e-ISBN-10: 1-84628-326-4 ISBN-13: 978-1-84628-320-8 e-ISBN-13: 978-1-84628-326-0 Printed on acid-free paper © Springer-Verlag London Limited 2006 Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patents Act 1988, this publication may only be reproduced, stored or trans- mitted, in any form or by any means, with the prior permission in writing of the publishers, or in the case of reprographic reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency. Enquiries concerning reproduction outside those terms should be sent to the publishers. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore free for general use. Product liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature. 9 8 7 6 5 4 3 2 1 Springer Science+Business Media, LLC Foreword The interstitial lung diseases, also called diffuse parenchymal lung diseases, are a diverse group of pulmonary disorders classified together because of similar clinical, roentgeno- graphic, physiologic, or pathologic features. During the past 50 years, we have experi- enced remarkable advances in the classification, diagnosis, and management of these diseases. Technological advances, particularly high-resolution computed tomography, bronchoalveolar lavage, and video-assisted thoracic surgery, have provided access to information that has vastly improved our understanding of these entities. In addition, genetic medicine, the use of new technologies (e.g., microarrays, mass spectroscopic analysis of proteins, and laser capture microdissection) and the development of animal models have led to better understanding of the pathogenesis of these disorders. Unfortunately, patients with diffuse parenchymal lung disease continue to present a difficult diagnostic and management challenge to clinicians. A major reason is that the topic of “interstitial lung disease” is vast and difficult to grasp. Some 25 years ago when I first became interested in interstitial lung diseases, there was no ready source of infor- mation relating specifically to these processes. Even today, there is a need for a compre- hensive, yet easy to read, manual of the key information about the important interstitial lung diseases. The purpose of this atlas is to provide the clinician, from medical student to lung spe- cialist, with a ready reference helpful in their attempts to master this topic and to provide guidance in their daily practice. The subject of interstitial lung disease is inherently mul- tidisciplinary; consequently, the authors have provided a consistent approach to each entity that includes the key clinical, physiologic, radiologic, and pathologic features. The Clinical Atlas of Interstitial Lung Disease is composed of 37 chapters loosely divided into six sections. The first section provides a historical background to the inter- stitial lung diseases and an overview of the basis for recognizing the key features that allow a specific diagnosis to be achieved. The second section is dedicated to the inter- stitial lung diseases of unknown etiology, including sarcoidosis, the idiopathic intersti- tial pneumonias, and eosinophilic pneumonias. The third section describes interstitial lung diseases of known etiology (e.g., drug-induced, radiation, hypersensitivity pneu- monitis, and pneumoconioses). The fourth section addresses interstitial lung diseases associated with the connective tissue diseases and pulmonary vasculitidies. The fifth section deals with a number of specific entities (e.g., alveolar proteinosis, lymphangi- oleiomyomatosis, and Langerhans cell histiocytosis). The final section devotes several chapters to the pulmonary manifestations of systemic diseases, such as paraproteine- mias, liver and gastrointestinal disease, and malignancy. We owe a debt of gratitude to all those who were involved in producing this Clinical Atlas of Interstitial Lung Disease. The authors have succeeded in creating a readable, concise atlas that is up to date and user friendly. Talmadge E. King, Jr., M.D. Department of Medicine University of California San Francisco; and San Francisco General Hospital San Francisco, California v ...